{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:06:57Z","timestamp":1784758017153,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Translational Research Grant of NCRCH","award":["No. 2021WWB07"],"award-info":[{"award-number":["No. 2021WWB07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02287-0","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T12:02:57Z","timestamp":1705924977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p\/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase\/Akt pathway"],"prefix":"10.1007","volume":"41","author":[{"given":"XueFeng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3477-9530","authenticated-orcid":false,"given":"JianMin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"6","key":"2287_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini A, et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017;23(6):692\u2013702.","journal-title":"Nat Med"},{"issue":"8","key":"2287_CR2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619\u201330.","journal-title":"Blood"},{"issue":"9584","key":"2287_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet (London, England). 2007;370(9584):342\u201350.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"2287_CR4","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker B. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640\u201353.","journal-title":"Blood"},{"issue":"4","key":"2287_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1158\/1078-0432.CCR-13-3317","volume":"21","author":"L Wu","year":"2015","unstructured":"Wu L, et al. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Clin Cancer Res\u202f: Off J Am Assoc Cancer Res. 2015;21(4):833\u201343.","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"6","key":"2287_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/15384047.2019.1579958","volume":"20","author":"J Wu","year":"2019","unstructured":"Wu J, et al. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for chronic myeloid leukemia (CML). Cancer Biol Ther. 2019;20(6):877\u201385.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"2287_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","volume":"6","author":"H Zhou","year":"2015","unstructured":"Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6(6):403\u201312.","journal-title":"Protein Cell"},{"issue":"3","key":"2287_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2141.1971.tb03436.x","volume":"21","author":"B Pedersen","year":"1971","unstructured":"Pedersen B, Hayhoe F. Cellular changes in chronic myeloid leukaemia. Br J Haematol. 1971;21(3):251\u20136.","journal-title":"Br J Haematol"},{"issue":"3","key":"2287_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/bfgp\/elv059","volume":"15","author":"X Wang","year":"2016","unstructured":"Wang X, et al. Noncoding RNAs and their functional involvement in regulation of chronic myeloid leukemia. Brief Funct Genomics. 2016;15(3):239\u201348.","journal-title":"Brief Funct Genomics"},{"issue":"1","key":"2287_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hon.2776","volume":"39","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. The role of long non-coding RNAs and downstream signaling pathways in leukemia progression. Hematol Oncol. 2021;39(1):27\u201340.","journal-title":"Hematol Oncol"},{"issue":"1","key":"2287_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41420-021-00665-z","volume":"7","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Biological functions and clinical significance of long noncoding RNAs in bladder cancer. Cell death discovery. 2021;7(1):278.","journal-title":"Cell death discovery"},{"key":"2287_CR12","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2021.3297","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Long noncoding RNA H19 accelerates tenogenic differentiation by modulating miR-140\u20135p\/VEGFA signaling. Eur J Histochem\u202f: Eur J Histochem. 2021. https:\/\/doi.org\/10.4081\/ejh.2021.3297.","journal-title":"Eur J Histochem : Eur J Histochem"},{"key":"2287_CR13","doi-asserted-by":"publisher","first-page":"153303382110521","DOI":"10.1177\/15330338211052150","volume":"20","author":"H Dai","year":"2021","unstructured":"Dai H, et al. LncRNA OIP5-AS1 promotes the autophagy-related imatinib resistance in chronic myeloid leukemia cells by regulating miR-30e-5p\/ATG12 Axis. Technol Cancer Res Treat. 2021;20:15330338211052150.","journal-title":"Technol Cancer Res Treat"},{"key":"2287_CR14","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.12659\/MSM.916661","volume":"25","author":"B Gao","year":"2019","unstructured":"Gao B, Li S, Li G. Long noncoding RNA (lncRNA) small nucleolar RNA host gene 5 (SNHG5) regulates proliferation, differentiation, and apoptosis of K562 cells in chronic myeliod leukemia. Med Sci Monitor\u202f: Int Med J Exp Clin Res. 2019;25:6812\u20139.","journal-title":"Med Sci Monitor : Int Med J Exp Clin Res"},{"issue":"8","key":"2287_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41419-020-02821-2","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, et al. Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC. Cell Death Dis. 2020;11(8):643.","journal-title":"Cell Death Dis"},{"key":"2287_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12935-019-1057-x","volume":"19","author":"L Han","year":"2019","unstructured":"Han L, et al. SNHG29 regulates miR-223-3p\/CTNND1 axis to promote glioblastoma progression via Wnt\/\u03b2-catenin signaling pathway. Cancer Cell Int. 2019;19:345.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"2287_CR17","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/15384047.2020.1831373","volume":"21","author":"Q Pang","year":"2020","unstructured":"Pang Q, et al. LRRC75A-AS1 targets miR-199b-5p\/PDCD4 axis to repress multiple myeloma. Cancer Biol Ther. 2020;21(11):1051\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"2287_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1177\/1535370219874339","volume":"244","author":"J Chen","year":"2019","unstructured":"Chen J, et al. Long noncoding RNA LRRC75A-AS1 inhibits cell proliferation and migration in colorectal carcinoma. Exp Biol Med (Maywood, NJ). 2019;244(14):1137\u201343.","journal-title":"Exp Biol Med (Maywood, N.J.)"},{"key":"2287_CR19","doi-asserted-by":"publisher","first-page":"839876","DOI":"10.3389\/fcell.2022.839876","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao S, Chen J. Development of an inflammation-related lncRNA-miRNA-mRNA network based on competing endogenous RNA in breast cancer at single-cell resolution. Front Cell Dev Biology. 2022;10:839876.","journal-title":"Front Cell Dev Biology"},{"issue":"2","key":"2287_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/0975-7406.129172","volume":"6","author":"B Ramesh","year":"2014","unstructured":"Ramesh B, et al. Comparative study on anti-oxidant and anti-inflammatory activities of Caesalpinia crista and Centella asiatica leaf extracts. J Pharm Bioallied Sci. 2014;6(2):86\u201391.","journal-title":"J Pharm Bioallied Sci"},{"issue":"8","key":"2287_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41419-021-04015-w","volume":"12","author":"C Zhong","year":"2021","unstructured":"Zhong C, et al. Autophagy-related circRNA evaluation reveals hsa_circ_0001747 as a potential favorable prognostic factor for biochemical recurrence in patients with prostate cancer. Cell Death Dis. 2021;12(8):726.","journal-title":"Cell Death Dis"},{"key":"2287_CR22","first-page":"5189549","volume":"2020","author":"J Xu","year":"2020","unstructured":"Xu J, et al. Identifying dysregulated lncRNA-associated ceRNA network biomarkers in CML based on dynamical network biomarkers. Biomed Res Int. 2020;2020:5189549.","journal-title":"Biomed Res Int"},{"key":"2287_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.gene.2017.01.004","volume":"607","author":"Y Lu","year":"2017","unstructured":"Lu Y, et al. Long noncoding RNA HULC promotes cell proliferation by regulating PI3K\/AKT signaling pathway in chronic myeloid leukemia. Gene. 2017;607:41\u20136.","journal-title":"Gene"},{"issue":"2","key":"2287_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1034\/j.1600-0609.2002.01549.x","volume":"69","author":"H Spets","year":"2002","unstructured":"Spets H, et al. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol. 2002;69(2):76\u201389.","journal-title":"Eur J Haematol"},{"issue":"3","key":"2287_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1586\/17474086.2015.1026321","volume":"8","author":"J Huang","year":"2015","unstructured":"Huang J, Fairbrother W, Reed J. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies. Expert Rev Hematol. 2015;8(3):283\u201397.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2287_CR26","first-page":"490","volume":"11","author":"K Wu","year":"2018","unstructured":"Wu K, et al. miR-483-3p promotes proliferation and migration of neuroblastoma cells by targeting PUMA. Int J Clin Exp Pathol. 2018;11(2):490\u2013501.","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"2287_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/cbin.10585","volume":"40","author":"J Ma","year":"2016","unstructured":"Ma J, et al. miR-483-3p plays an oncogenic role in esophageal squamous cell carcinoma by targeting tumor suppressor EI24. Cell Biol Int. 2016;40(4):448\u201355.","journal-title":"Cell Biol Int"},{"issue":"3","key":"2287_CR28","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/jcp.29167","volume":"235","author":"M Menbari","year":"2020","unstructured":"Menbari M, et al. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene. J Cell Physiol. 2020;235(3):2631\u201342.","journal-title":"J Cell Physiol"},{"issue":"2","key":"2287_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/mc.23138","volume":"59","author":"J Guo","year":"2020","unstructured":"Guo J, et al. Upregulation of DKK3 by miR-483-3p plays an important role in the chemoprevention of colorectal cancer mediated by black raspberry anthocyanins. Mol Carcinog. 2020;59(2):168\u201378.","journal-title":"Mol Carcinog"},{"issue":"3","key":"2287_CR30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/cancers14030839","volume":"14","author":"D Leardini","year":"2022","unstructured":"Leardini D, et al. Role of CBL mutations in cancer and non-malignant phenotype. Cancers. 2022;14(3):839.","journal-title":"Cancers"},{"issue":"8","key":"2287_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/1078-0432.CCR-13-2490","volume":"21","author":"M Liyasova","year":"2015","unstructured":"Liyasova M, Ma K, Lipkowitz S. Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(8):1789\u201394.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"2287_CR32","doi-asserted-by":"publisher","first-page":"103878","DOI":"10.1016\/j.cellimm.2018.11.002","volume":"340","author":"R Tang","year":"2019","unstructured":"Tang R, Langdon W, Zhang J. Regulation of immune responses by E3 ubiquitin ligase Cbl-b. Cell Immunol. 2019;340:103878.","journal-title":"Cell Immunol"},{"issue":"6","key":"2287_CR33","first-page":"366","volume":"119","author":"D Akin","year":"2018","unstructured":"Akin D, et al. Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia. Bratisl Lek Listy. 2018;119(6):366\u201372.","journal-title":"Bratisl Lek Listy"},{"issue":"7","key":"2287_CR34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00439-015-1550-9","volume":"134","author":"A Pathak","year":"2015","unstructured":"Pathak A, et al. Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family. Hum Genet. 2015;134(7):775\u201387.","journal-title":"Hum Genet"},{"issue":"5","key":"2287_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/bjh.12068","volume":"159","author":"E Coenen","year":"2012","unstructured":"Coenen E, et al. CBL mutations do not frequently occur in paediatric acute myeloid leukaemia. Br J Haematol. 2012;159(5):577\u201384.","journal-title":"Br J Haematol"},{"issue":"4","key":"2287_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41374-021-00638-x","volume":"102","author":"X Sun","year":"2022","unstructured":"Sun X, et al. microRNA-155\u20135p initiates childhood acute lymphoblastic leukemia by regulating the IRF4\/CDK6\/CBL axis. Lab Investig J Tech Methods Pathol. 2022;102(4):411\u201321.","journal-title":"Lab Investig J Tech Methods Pathol"},{"issue":"16","key":"2287_CR37","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1002\/pmic.200600109","volume":"6","author":"X Liang","year":"2006","unstructured":"Liang X, et al. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics. 2006;6(16):4554\u201364.","journal-title":"Proteomics"},{"issue":"1","key":"2287_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2287_CR39","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","volume":"47","author":"N Jiang","year":"2020","unstructured":"Jiang N, et al. Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587\u2013629.","journal-title":"Mol Biol Rep"},{"issue":"12","key":"2287_CR40","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","volume":"72","author":"J Bertacchini","year":"2015","unstructured":"Bertacchini J, et al. Targeting PI3K\/AKT\/mTOR network for treatment of leukemia. Cell Mol Life Sci: CMLS. 2015;72(12):2337\u201347.","journal-title":"Cell Mol Life Sci: CMLS"},{"issue":"1","key":"2287_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","volume":"38","author":"P Singh","year":"2021","unstructured":"Singh P, et al. Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: a review. Med Oncol (Northwood, London, England). 2021;38(1):10.","journal-title":"Med Oncol (Northwood, London, England)"},{"issue":"6","key":"2287_CR42","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/onc.2013.596","volume":"34","author":"S Bunda","year":"2015","unstructured":"Bunda S, et al. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K\/AKT pathway. Oncogene. 2015;34(6):789\u201397.","journal-title":"Oncogene"},{"issue":"9","key":"2287_CR43","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3390\/cells10092382","volume":"10","author":"J Chekmarev","year":"2021","unstructured":"Chekmarev J, Azad M, Richardson D. The oncogenic signaling disruptor, NDRG1: molecular and cellular mechanisms of activity. Cells. 2021;10(9):2382.","journal-title":"Cells"},{"issue":"16","key":"2287_CR44","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1182\/blood.2020006528","volume":"137","author":"R Belizaire","year":"2021","unstructured":"Belizaire R, et al. CBL mutations drive PI3K\/AKT signaling via increased interaction with LYN and PIK3R1. Blood. 2021;137(16):2209\u201320.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02287-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02287-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02287-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T18:16:14Z","timestamp":1706724974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02287-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02287-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study was approved by the Ethics Committee of The Second Hospital of Hebei Medical University(HB20180910) and written informed consent was provided by all patients prior to the study start. All procedures were performed in accordance with the ethical standards of the Institutional Review Board and The Declaration of Helsinki, and its later amendments or comparable ethical standards. And all animal experiments were complied with the ARRIVE guidelines and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The experiments were approved by the Institutional Animal Care and Use Committee of The Second Hospital of Hebei Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from each subject.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"60"}}